Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Aug;118(8):1255-9.
doi: 10.1007/s00702-011-0623-8. Epub 2011 Apr 2.

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study

Michael Rainer  1 , A Wuschitz, C Jagsch, C Erb, J-J Chirikdjian, H A M Mucke
Affiliations
Comparative Study

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study

Michael Rainer et al. J Neural Transm (Vienna). 2011 Aug.

Abstract

Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.

PubMed Disclaimer

References

    1. Int J Geriatr Psychiatry. 2008 May;23(5):546-51 - PubMed
    1. N Engl J Med. 2003 Apr 3;348(14):1333-41 - PubMed
    1. Int J Geriatr Psychiatry. 2009 May;24(5):532-8 - PubMed
    1. J Alzheimers Dis. 2007 Jul;11(4):471-9 - PubMed
    1. JAMA. 2004 Jan 21;291(3):317-24 - PubMed

Publication types

LinkOut - more resources